Stockscreener 앱 받기
3.39
0.29%
-0.010
시간 외 거래:
3.39
전일 마감가:
$3.40
열려 있는:
$3.41
하루 거래량:
486.24K
Relative Volume:
0.49
시가총액:
$431.18M
수익:
$79.18M
순이익/손실:
$-136.99M
주가수익비율:
-3.2142
EPS:
-1.0547
순현금흐름:
$-120.11M
1주 성능:
+4.31%
1개월 성능:
-17.11%
6개월 성능:
-15.67%
1년 성능:
+52.02%
1일 변동 폭
$3.355
$3.45
1주일 범위
$3.10
$3.45
52주 변동 폭
$2.045
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.39 | 432.45M | 79.18M | -136.99M | -120.11M | -1.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics targets $600M-$1B US peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June - MSN
ADC Therapeutics Announces Investigator-Initiated Study Abstract - GuruFocus
ADC reports data from lymphoma trial, streamlines operations - MSN
ADCT News | ADC THERAPEUTICS SA (NYSE:ADCT) - ChartMill
TradingKey - TradingKey
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update - Quantisnow
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
HC Wainwright & Co. Maintains ADC Therapeutics (ADCT) Buy Recommendation - MSN
ADC Therapeutics (ADCT) Earnings Date and Reports 2026 - MarketBeat
Q2 EPS Estimate for ADC Therapeutics Decreased by Analyst - MarketBeat
Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report - simplywall.st
ADC Therapeutics Q1 2026 Earnings: Revenue Growth and ZYNLONTA MilestonesNews and Statistics - IndexBox
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT) - Seeking Alpha
ADC Therapeutics SA 2026 Q1ResultsEarnings Call Presentation (NYSE:ADCT) 2026-05-05 - Seeking Alpha
ADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank Of Canada - MarketBeat
ADC Therapeutics (NYSE:ADCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript - Insider Monkey
ADC Therapeutics SA Q1 2026 Financial Results: Revenue, Losses, and Forward-Looking Statements - Minichart
ADC Therapeutics to Host First Quarter 2026 Financial Results Co - GuruFocus
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call - Benzinga
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary - Yahoo Finance
ADC Therapeutics Reports Narrower Q1 2026 Loss, Beats Estimates - AlphaStreet
ADC Therapeutics Q1 2026: $0.13/share Loss Beats Estimates — Deep Dive - AlphaStreet
ADC Therapeutics (NYSE: ADCT) posts Q1 2026 loss $33M, cash $231M - Stock Titan
ADC Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
ADC Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Reports Q1 2026 Financial Results and Updates – NYSE: ADCT - Minichart
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ADC Therapeutics Q1 Earnings Call Highlights - MarketBeat
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
ADC Therapeutics : (ADCT 1Q 2026 Earnings) - marketscreener.com
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) Beats Q1 Estimates, But Market Reaction Remains Subdued - ChartMill
The biopharmaceutical company ADC Therapeutics SA recently disclosed its latest financial data, showing that as of March 31, 2026, the company's cash and cash equivalents totaled 231 million USD. - Bitget
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q1 2026 Earnings - Quiver Quantitative
ADC Therapeutics reports Q1 2026: $20.0M net product revenue, $32.97M net loss - TradingView
ADC Therapeutics (NYSE: ADCT) narrows Q1 loss, sees cash runway into 2028 - Stock Titan
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - marketscreener.com
Earnings Scheduled For May 4, 2026 - Benzinga
MSN Money - MSN
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - GuruFocus
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance Singapore
ADC Therapeutics SA expected to post a loss of 21 cents a shareEarnings Preview - TradingView
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan – Company Announcement - Financial Times
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 - Nasdaq
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics rises on $60M PIPE financing - MSN
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):